The
antiphospholipid syndrome (APS) is characterized by the presence of
antiphospholipid antibodies (aPL) in patients with thromboembolic complications. In APS, most aPL are
autoantibodies to
beta2-glycoprotein I and
prothrombin, which play a major role in the APS pathogenesis. Nevertheless,
antibodies with the same
antigen specificity are also found in aPL patients with
leprosy, in whom thromboembolic complications are uncommon. The in vivo upregulation of the
tissue factor (TF) pathway and the imbalance of
cytokines have been proposed as potential mechanisms of
thrombosis in the APS. We measured the circulating levels of TF,
interleukin 6 (IL-6),
IL-6 receptor (sIL-6R),
tumor necrosis factor (
TNF-alpha) and
interferon gamma (IFN-gamma) in 83 patients with autoimmune aPL (42 with and 41 without clinical features of definite primary APS), 48
leprosy patients (33 with aPL) and 48 normal controls. There was a trend (P = 0.06) to higher median sTF in patients with autoimmune aPL (139 pg/mL) compared with
leprosy patients (103.5 pg/mL) and controls (123 pg/mL). In addition, the frequency of raised sTF levels (> 187 pg/mL) was significantly higher in the group with autoimmune aPL [22.9% (APS 21.4%, non-APS 24.4%)] but not in
leprosy (10.4%) compared with controls (4.2%). Elevated levels of
IL-6 and
TNF-alpha and a trend to lower IFN-gamma were found in patients with definite APS.
Leprosy patients with aPL, however, had increased
TNF-alpha and IFN-gamma but normal
IL-6 levels. Levels of sIL-6R did not differ between controls and either patients with autoimmune aPL or
leprosy. The different
cytokine profiles as well as differences in circulating levels of TF might contribute to the high thrombotic risk found in patients with autoimmune aPL but not in
leprosy related aPL patients.